July 2024 - Page 8 of 12

APACC On-site Report | Dr. Ye Zhang: “Pay it Forward” – A New Strategy to Increase STD Testing Rates

By Ren Jiamo 2024.07.12

In the era of 5G, the consumption and entertainment habits of sexually active young people have changed significantly, including activities such as drinking coffee, shopping, watching movies, and taking selfies. It is essential to continuously explore and improve strategies for testing and preventing sexually transmitted diseases (STDs) that are tailored to the times and local conditions. At the recent 9th Asia Pacific AIDS & Co-infections Conference (APACC 2024), Dr. Ye Zhang from the Kirby Institute at the University of New South Wales, Australia, presented "Innovations in Implementation Strategies of Delivery Models," introducing the "Pay it Forward" strategy and sharing more insights in an interview with Infectious Diseases Frontier.

Dr. Brigitte Quenum: Breaking the “isolated island” model and integrating resources to address HIV prevention and control challenges in Asia and the Pacific

By Mourabit Halima 2024.07.12

Recently, at the 9th Asia-Pacific AIDS& Co- Infections Conference 2024 (APACC 2024), Dr. Brigitte Quenum, UNAIDS Regional Office for Asia and the Pacific, delivered a speech entitled "Challenges & Success in the Region" and in an interview with Infectious Disease Frontier,she introduced the challenges and solutions of HIV/AIDS prevention and treatment in the Asia- Pacific region, with particular emphasis on breaking the "isolated island" model of government or community fighting alone and achieving the integration of multiple resources.

Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

By Mourabit Halima 2024.07.12

Clinical cure of chronic hepatitis B (CHB), also known as functional cure, is achieved when patients remain HBsAg negative after stopping treatment, with or without the presence of anti-HBs, HBV DNA levels below the detection limit, and normal liver biochemical indicators. However, HBV covalently closed circular DNA (cccDNA) may still persist in the nuclei of liver cells in these patients. Therefore, clearing HBV cccDNA remains a major obstacle to achieving complete virological cure of CHB. Recently, at the 17th National Clinical Conference on Liver Diseases held in Shenyang, "Hepatology Digest" invited Professor Jun Cheng from Hebei Wutu Pharmaceutical Co., Ltd. to discuss the clearance of HBV cccDNA and other related issues.

Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

By Mourabit Halima 2024.07.12

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage breast cancer, CDK4/6 inhibitors have also shown positive results and have been approved for indications. The 2024 ASCO conference presented multiple advancements in the adjuvant treatment of HR+/HER2- early-stage breast cancer with CDK4/6 inhibitors. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum, Oncology Frontier invited Professor Hong Hu from Shenzhen People's Hospital, and Professor Yuntao Wei from Liaoning Cancer Hospital & Institute to elaborate on and discuss the research progress of CDK4/6 inhibitors in adjuvant therapy for HR+ early-stage breast cancer.

APACC Live Report: Dr. Rongqiu Liu from Professor Hua You’s Team Shares Research Findings and Management Strategies for HIV-Associated Malignancies

By Ren Jiamo 2024.07.10

For HIV patients, encountering malignancies is akin to a double blow, exacerbating their already challenging condition. HIV-infected individuals commonly face opportunistic diseases such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Enhancing early diagnosis and treatment of HIV-associated tumors and refining clinical management strategies are critical areas for clinical and research exploration. At the recent 9th Asia Pacific AIDS and Co-infections Conference (APACC 2024), Dr. Rongqiu Liu from Professor Hua You’s team at Children's Hospital of Chongqing Medical University presented two studies on risk prediction models for HIV-associated lymphomas and received conference funding support. "Infectious Diseases Frontier" interviewed Dr. Liu on-site to discuss her team’s research findings and management strategies for patients with HIV-associated malignancies.

Professor Houwen Lin: The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases

By Mourabit Halima 2024.07.10

With the increasing aging population in China, major chronic diseases have become the leading cause of death and the most significant disease burden for Chinese residents. As an essential means of treating chronic diseases, medications urgently require scientific, rational, and precise usage and management. At a domestic academic conference, Professor Houwen Lin from Shanghai Jiao Tong University School of Medicine, gave a remarkable academic report titled "The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases." He provided a detailed introduction of how the clinical pharmacy team at Renji Hospital, driven by clinical needs, established key technologies for precise medication and new drug clinical positioning for major chronic diseases such as cardiovascular metabolism, rheumatology, and oncology. This article summarizes the report's content for the readers of Hepatology Digest.

ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

By Mourabit Halima 2024.07.10

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. During this prestigious event, Oncology Frontier-Hematology Frontier had the honor of interviewing Academician Heyu Ni from the Canadian Academy of Health Sciences, who also served as the Chair of the Joint ISTH Congress and Global Chinese Thrombosis and Hemostasis Conference. In this interview, Academician Ni shared his extensive academic experience and unique insights, providing us with valuable academic reflections and perspectives. We have organized this interview into an article for our readers.

Xinghai Forum: Professor Bin Hua and Juliang Zhang Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast

By Mourabit Halima 2024.07.10

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Bin Hua from Beijing Hospital and Professor Juliang Zhang from Xijing Hospital of Air Force Medical University discuss these latest research advancements in depth.

ISTH China’s Voice | Professor Xuefeng Wang’s Team: Single-cell sequencing of PBMCs from hemophilia A and hemophilia B patients with inhibitors reveals different immune responses to FVIII and FIX after replacement therapy

By Mourabit Halima 2024.07.10

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars worldwide with its profound academic impact and rich content. The "ISTH China's Voices" column of Oncology Frontier-Hematology Frontier aims to showcase outstanding research achievements from the Chinese academic community at ISTH. In this issue, we present a research finding from Dr. Enhao Li of Professor Xuefeng Wang's team at Ruijin Hospital, Shanghai Jiaotong University School of Medicine. Dr. Li's oral presentation at ISTH delved into the differential immune responses to FVIII and FIX in hemophilia A (HA) and hemophilia B (HB) patients, providing valuable academic insights for the hematology field.

Professor Sifeng Tao and Hui Liu Discuss Advances in (Neo)Adjuvant Treatment and Personalized Strategies for Triple-Negative Breast Cancer

By Mourabit Halima 2024.07.10

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Sifeng Tao from The Second Affiliated Hospital Zhejiang University School of Medicine and Professor Hui Liu fro